Form 8-K - Current report:
SEC Accession No. 0000950170-22-011723
Filing Date
2022-06-16
Accepted
2022-06-16 08:36:56
Documents
12
Period of Report
2022-06-10
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K fnch-20220610.htm   iXBRL 8-K 60634
  Complete submission text file 0000950170-22-011723.txt   177836

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fnch-20220610_pre.xml EX-101.PRE 9850
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fnch-20220610_lab.xml EX-101.LAB 13342
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fnch-20220610.xsd EX-101.SCH 2484
6 EXTRACTED XBRL INSTANCE DOCUMENT fnch-20220610_htm.xml XML 4711
Mailing Address 200 INNER BELT ROAD SOMERVILLE MA 02143
Business Address 200 INNER BELT ROAD SOMERVILLE MA 02143 617-229-6499
Finch Therapeutics Group, Inc. (Filer) CIK: 0001733257 (see all company filings)

EIN.: 823433558 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40227 | Film No.: 221019398
SIC: 2836 Biological Products, (No Diagnostic Substances)